FF305 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 | 行股份（不包括庫存股 | 庫存股份數目 | | | | | | 目 | 份）數目百分比 (註3) | | | | | 於下列日期開始時的結存(註1) | 2025年8月6日 | | 2,485,141,055 | | 0 | 2,485,141,055 | | 1). 其他 (請註明) | | | % | | | | | 參見B部 | | | | | | | | 變動日期 | 2025年8月7日 | | | | | | | 於下列日期結束 ...

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. is seeking to go public on the Hong Kong Stock Exchange, highlighting its innovative drug development in the field of bacterial infections, particularly targeting Helicobacter pylori infections, despite facing significant financial challenges [2][3]. Company Overview - Founded in 2013, Danuo Pharmaceutical has completed seven rounds of financing, with a post-investment valuation of 2.013 billion RMB in its latest round [2]. - The company’s core product, Rifoternizole, is positioned to be the first new molecular entity approved for treating Helicobacter pylori infections globally [3][4]. Product Pipeline - Danuo has developed a differentiated pipeline consisting of seven innovative assets, including three core products: Rifoternizole (TNP-2198), Rifocquinone (TNP-2092) injection, and TNP-2092 oral formulation [3]. - Rifoternizole is the most advanced product, with plans to submit a new drug application to the National Medical Products Administration by August 2025 [3]. Financial Situation - The company reported a cumulative loss of 376 million RMB in 2023, with a net debt of 932 million RMB and cash reserves of only 146 million RMB as of March 2025 [6][8]. - Research and development expenses accounted for a significant portion of the losses, with 90.7%, 82%, and 65.3% of total R&D spending allocated to core product development during the reporting period [6]. Market Potential - The global market for antibacterial drugs is projected to grow from 45.5 billion USD in 2024 to 84.3 billion USD by 2035, indicating a robust industry outlook despite challenges in the Chinese market [9]. Shareholder and Supplier Dynamics - WuXi AppTec, a major shareholder, also serves as a key supplier, raising potential concerns regarding the independence and fairness of related transactions [9][11]. - The largest supplier, identified as Supplier B, accounted for 53.5% of total procurement in the first quarter of 2025, further emphasizing the intertwined relationship between Danuo and WuXi [11][12].

相关事件 药明康德(02359.HK)完成配售7380万股 药明康德(02359.HK)8月6日耗资2799.17万元回购29.81万股A股 格隆汇8月7日丨药明康德(02359.HK)公告，董事会欣然宣布已达成所有条件并于2025年8月7日完成配 售。配售代理已根据配售协议的条款及条件按每股配售股份配售价104.27港元向不少于六名独立承配人 成功配售合共7380万股配售股份。 ...

配售的募集资金净额为76.47亿港元，将按以下方式投入使用：约90%将用于加速推进全球布局和产能 建设;及约10%将用于一般公司用途。 智通财经APP讯，药明康德(02359)发布公告，董事会欣然宣布已达成所有条件并于2025年8月7日完成配 售。配售代理已根据配售协议的条款及条件按每股配售股份配售价104.27港元向不少于六名独立承配人 成功配售合共7380万股配售股份。经董事作出一切合理查询后所知、所悉及所信，承配人及其各自的最 终实益拥有人均为独立于本公司及本公司关连人士且与本公司及本公司关连人士概无关连的第三方。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月7日 第 1 頁 共 12 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司 法權區內刊發或派發。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非，亦不構成於美國（定義見1933年《美國證券法》（「《證券法》」）S規例）出售證券的 要約或邀請及其任何部分。本公告或其任何內容或其副本亦不得攜進美國境內或於美國境內 或在刊發或派發本公告屬違法的任何其他司法權區內直接或間接派發。除非本公告所指證券 根據《證券法》辦理登記或獲豁免遵守《證券法》的登記規定，否則有關證券未曾亦不會根據《證 券法》登記，且不得在美國境內提呈發售、出售或以其他方式轉讓。本公司並無計劃在美國 登記本公告所述任何證券或在美國公開發售任何證券。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 根據一般授權完成 ...

沪指8月7日上涨0.16%，申万所属行业中，今日上涨的有18个，涨幅居前的行业为有色金属、美容护 理，涨幅分别为1.20%、0.99%。跌幅居前的行业为医药生物、电力设备，跌幅分别为0.92%、0.74%。 医药生物行业位居今日跌幅榜首位。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688166 | 博瑞医药 | -5.70 | 3.89 | 23275.85 | | 002173 | 创新医疗 | 10.01 | 30.10 | 22618.18 | | 000710 | 贝瑞基因 | 5.26 | 23.64 | 20015.67 | | 300289 | 利德曼 | 20.02 | 21.71 | 17141.65 | | 002022 | 科华生物 | 9.96 | 12.63 | 15290.70 | | 300981 | 中红医疗 | 19.99 | 8.06 | 11833.89 | | 300760 | 迈瑞医疗 | 1.09 | 0.60 | 11395.45 | | 00 ...

Core Insights - The article discusses the AH premium rates of various stocks as of August 7, highlighting the top and bottom performers in terms of premium rates and deviation values [1][2]. Group 1: Top AH Premium Rates - Northeast Electric (00042) leads with an AH premium rate of 831.03%, followed by Hongye Futures (03678) at 233.11% and Andeli Juice (02218) at 211.82% [1][2]. - The top three stocks with the highest deviation values are Andeli Juice (02218) at 29.36%, Kinglong Magnet (06680) at 18.33%, and Zhaoyan New Drug (06127) at 14.37% [1][2]. Group 2: Bottom AH Premium Rates - The stocks with the lowest AH premium rates include Heng Rui Pharmaceutical (01276) at -6.07%, China Merchants Bank (03968) at 5.94%, and Zijin Mining (02899) at 8.09% [1][2]. - The bottom three stocks with the lowest deviation values are BYD Company (01211) at -185.95%, Chenming Paper (01812) at -71.15%, and Northeast Electric (00042) at -62.30% [1][2]. Group 3: Detailed Premium and Deviation Data - The top ten AH stocks by premium rate include Fudan Zhangjiang (01349) at 205.08% and Zhejiang Shibao (01057) at 190.91% [2]. - The bottom ten AH stocks by premium rate include Midea Group (00300) at 8.93% and Weichai Power (02338) at 9.41% [2]. - The deviation values for the top ten AH stocks show significant positive deviations for Andeli Juice, while BYD Company shows a substantial negative deviation [2][3].

Group 1 - The core viewpoint of the report is that Zhongyou Securities has given WuXi AppTec (603259.SH, latest price: 91.13 yuan) a buy rating due to its strong business performance [2] - The Chemistry business revenue continues to grow rapidly, while the Testing business revenue has stabilized [2] - The company has maintained a rapid growth in its order backlog and has raised its full-year revenue guidance [2]

Core Viewpoint - WuXi AppTec's profitability is steadily improving, leading to an upward revision of its full-year performance guidance [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 20.8 billion yuan (+20.6% year-on-year), with continuous operating business revenue at 20.41 billion yuan (+24.2% year-on-year) [1] - The net profit attributable to shareholders reached 8.56 billion yuan (+101.9%), while the adjusted Non-IFRS net profit was 6.31 billion yuan (+44.4%) [1] - For Q2 2025, operating revenue was 11.15 billion yuan (+20.4%), with continuous operating business revenue at 11.02 billion yuan (+24.9%) [1] Business Segment Analysis - Chemistry business revenue for the first half of 2025 was 16.3 billion yuan (+33.5%), with an adjusted Non-IFRS gross margin of 49.0% (+5.2 percentage points) [2] - The TIDES business saw significant growth, with revenue of 5.03 billion yuan (+141.6%) in the first half of 2025, and a backlog of orders increasing by 48.8% year-on-year [2] - The Testing business revenue decreased slightly to 2.69 billion yuan (-1.2%), with a decline in adjusted Non-IFRS gross margin to 25.1% [3] Order Backlog and Guidance - As of June 30, 2025, the company had a continuous operating business backlog of 56.69 billion yuan (+37.2%) [4] - The full-year revenue growth guidance for 2025 has been revised to 13%-17%, up from the previous 10%-15% [4] Profit Forecast and Investment Recommendation - Revenue projections for 2025, 2026, and 2027 are 43.29 billion yuan, 49.02 billion yuan, and 55.85 billion yuan, respectively, with year-on-year growth rates of 10.3%, 13.3%, and 13.9% [5] - The company is rated as a "buy" due to its leading position in the integrated drug development service platform and the expected recovery in its core Chemistry business [5]